Patents by Inventor Franco PATRONE

Franco PATRONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10512648
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitor to the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 24, 2019
    Assignees: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto Ballestrero, Irene Caffa, Valter Longo, Alessio Nencioni, Patrizio Odetti, Franco Patrone
  • Publication number: 20190105323
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitor to the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 11, 2019
    Applicants: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto BALLESTRERO, Irene CAFFA, Valter LONGO, Alessio NENCIONI, Patrizio ODETTI, Franco PATRONE
  • Patent number: 10117872
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 6, 2018
    Assignees: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto Ballestrero, Irene Caffa, Valter Longo, Alessio Nencioni, Patrizio Odetti, Franco Patrone
  • Publication number: 20170173020
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Application
    Filed: March 30, 2015
    Publication date: June 22, 2017
    Applicants: UNIVERSITÁ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto BALLESTRERO, Irene CAFFA, Valter LONGO, Alessio NENCIONI, Patrizio ODETTI, Franco PATRONE